Use of 13-HODE as a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia

Abstract

This invention relates to the regulation of vascular endothelium biocompatibility and to the inhibition of vessel wall cell and other types of cell hyperplasia following vessel wall dysfunction and/or injury. More particularly, the invention relates to the dietetic and pharmaceutical preparations of 13-hydroxyoctadeca-9Z, 11E-dienoic acid (13-HODE) and its use in reducing or inhibiting vessel wall hyperlasia and restoring vessel wall biocompatibility.

1 . A method of reducing or inhibiting cell hyperlasia and restoring vessel wall biocompatibility in a mammal or human in need of such treatment, comprising administering orally an amount of 13-hydroxyoctadeca-9Z, 11E-dienoic acid (13-HODE) effective to reduce or inhibit vessel wall thrombogenicity.  
   
   
       2 . The method of  claim 1 , wherein 13-HODE is administered as a pharmaceutical composition comprising 13-HODE and a pharmaceutically acceptable carrier, auxiliary, or excipient.  
   
   
       3 . The method of  claim 2 , wherein the carrier is a mono-, di- or triglyceride oil.  
   
   
       4 . The method of  claim 2 , wherein the carrier is selected from the group consisting of corn, sunflower, safflower, cottonseed, grape seed, olive, evening primrose, borage, fish body and fish liver oils.  
   
   
       5 . The method of  claim 2 , wherein the carrier is an ester of a fatty acid containing 16-26 carbon atoms and one or more double bonds.  
   
   
       6 . The method of  claim 2 , wherein the ester is selected from the group consisting of ethyl-eicosapentaenoic (ethyl-EPA), oleic, linoleic, alpha-linoleic, stearidonic, gamma-linolenic, dihomogammalinolenic, arachidonic, docosapentaenoic and docosahexaenoic (ethyl-DHA).  
   
   
       7 . The method of  claim 2 , wherein the composition further comprises a fat-soluble antioxidant selected from the group consisting of ascorbyl palmitate, tocopherols, and ascorbic acid in the presence of lecithin.  
   
   
       8 . The method of  claim 2 , wherein the composition further comprises an additive selected from the group consisting of aggregants, disaggregants, osmotic pressure regulating salts, buffers, sweeteners, and coloring agents.  
   
   
       9 . The method of  claim 2 , wherein the composition is administered as a formulation selected from the group consisting of tablets, dragees, capsules, granules, solution, suspensions, and lyophilized compositions.  
   
   
       10 . The method of  claim 1  for the treatment of a disease or condition selected from the group consisting of: cardiovascular or cerebrovascular disease; inflammatory or autoimmune disease; infection with bacteria, viruses, fungi, or protozoa; respiratory disease; gastrointestinal disease; renal or urinary tract disease; skin disease; neurological or psychiatric disease; disease of the reproductive system; diabetes, syndrome A or any complication of diabetes.  
   
   
       11 . The method of  claim 1  for the treatment of a disease or condition associated with overactive protein kinases.  
   
   
       12 . The method of  claim 11 , wherein the disease or condition is associated with increase in Protein Kinase C activity and/or an increase in Mitogen Activated Protein Kinase activity.  
   
   
       13 . The method of  claim 1  for the treatment of a disease or condition where endothelial function is disordered.  
   
   
       14 . The method of  claim 1  for the treatment of cancer or the metastatic spread of cancer.  
   
   
       15 . The method of  claim 1  for the prevention of cancer or the metastatic spread of cancer.